UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 202,616 Shares of Align Technology, Inc. $ALGN

Key Points

• UBS Asset Management increased its stake in Align Technology by 32.2% during the first quarter, acquiring an additional 202,616 shares, bringing their total to 832,313 shares valued at approximately $132.2 million.
• Align Technology's latest quarterly earnings report showed an EPS of $2.49, falling short of the consensus estimate of $2.57, with revenue dropping 1.6% year-over-year to $1.01 billion.
• Several analysts have recently cut their price targets for Align Technology, with a consensus average of $215.00, reflecting a cautious outlook amidst the company's stock buyback plan and recent earnings miss.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 32.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 832,313 shares of the medical equipment provider's stock after buying an additional 202,616 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 1.15% of Align Technology worth $132,221,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Orion Capital Management LLC purchased a new stake in Align Technology during the fourth quarter valued at about $42,000. Compagnie Lombard Odier SCmA purchased a new stake in Align Technology during the first quarter valued at about $32,000. Center for Financial Planning Inc. purchased a new stake in Align Technology during the first quarter valued at about $35,000. SVB Wealth LLC purchased a new stake in Align Technology during the first quarter valued at about $36,000. Finally, Mather Group LLC. boosted its position in Align Technology by 375.0% during the first quarter. Mather Group LLC. now owns 437 shares of the medical equipment provider's stock valued at $69,000 after buying an additional 345 shares during the period. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Align Technology

In related news, CEO Joseph M. Hogan purchased 7,576 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was bought at an average cost of $131.49 per share, with a total value of $996,168.24. Following the completion of the purchase, the chief executive officer directly owned 184,945 shares in the company, valued at approximately $24,318,418.05. This represents a 4.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.66% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ALGN has been the subject of several analyst reports. Zacks Research lowered shares of Align Technology from a "hold" rating to a "strong sell" rating in a research report on Monday, September 1st. Wells Fargo & Company lowered their price objective on shares of Align Technology from $246.00 to $199.00 and set an "overweight" rating for the company in a research note on Thursday, July 31st. Stifel Nicolaus lowered their price objective on shares of Align Technology from $275.00 to $200.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Morgan Stanley reaffirmed an "equal weight" rating and set a $154.00 price objective (down from $249.00) on shares of Align Technology in a research note on Thursday, July 31st. Finally, Piper Sandler lowered their price objective on shares of Align Technology from $250.00 to $190.00 and set an "overweight" rating for the company in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $215.00.

Align Technology Price Performance

ALGN stock traded up $2.22 during trading on Thursday, reaching $131.66. The company had a trading volume of 444,954 shares, compared to its average volume of 1,224,150. Align Technology, Inc. has a 52 week low of $127.70 and a 52 week high of $260.88. The company has a market cap of $9.54 billion, a P/E ratio of 22.17, a PEG ratio of 1.49 and a beta of 1.65. The business has a 50 day moving average of $156.67 and a 200 day moving average of $169.00.

Align Technology (NASDAQ:ALGN - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.57 by ($0.08). Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the company earned $2.41 earnings per share. Align Technology's quarterly revenue was down 1.6% on a year-over-year basis. Align Technology has set its Q3 2025 guidance at EPS. Research analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology declared that its Board of Directors has authorized a share buyback plan on Tuesday, August 5th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.